As the predominant pathway for the repair of DNA double-strand breaks (DSB), non-
homologous end joining (NHEJ) attenuates the efficacy of cancer treatment which relies on …

Non-homologous DNA end joining (NHEJ) is the major pathway for the repair of double-
strand breaks (DSBs) in human cells. Proteins involved in NHEJ pathway can become …

DNA-dependent protein kinase catalytic subunit (DNA-PKcs) is a distinct factor in the non-
homologous end-joining (NHEJ) pathway involved in DNA double-strand break (DSB) …

Nonhomologous end joining (NHEJ), one of the major DNA double‐strand break repair
pathways, plays a significant role in cancer cell proliferation and resistance to radio and …

Purpose: Radiation remains a mainstay for the treatment of nonmetastatic head and neck
squamous cell carcinoma (HNSCC), a malignancy characterized by a high rate of …

Many cancer therapies, including radiotherapy, induce DSBs as the major driving
mechanism for inducing cancer cell death. Thus, modulating DSB repair has immense …

Most cancer therapies involve a component of treatment that inflicts DNA damage in tumor
cells, such as double-strand breaks (DSBs), which are considered the most serious threat to …

The vast majority of cancer patients receive DNA-damaging drugs or ionizing radiation (IR)
during their course of treatment, yet the efficacy of these therapies is tempered by DNA …

Simple Summary Cancer onset and progression lead to a high rate of DNA damage, due to
replicative and metabolic stress. To survive in this dangerous condition, cancer cells switch …

DNA repair pathway inhibitors are a new class of anticancer drugs that are advancing in
clinical trials. Peposertib is an inhibitor of DNA-dependent protein kinase (DNA-PK), which is …